APOA1 and myeloid sarcoma: Lower CSF apo-AI levels in patients with a favourable course in our cohort may be linked to a lower degree of suppression of these pro-inflammatory cytokines by apo-AI, resulting in a more inflammatory disease phase as expected in relapsing-active MS.